FP-7 funded REDDSTAR will comprehensively examine if Stromal Stem Cells can safely control glycaemia and alleviate damage caused by 6 diabetic complications.
Our projects have gathered some wide-spread news lately. Here are a few media nuggets. Firstly, @FraunhoferIPT's role in @AutoCRAT2020 was featured at the @MEDICATradeFair, in their magazine and in videos 📽️🇩🇪 ! https://t.co/hFW6ucbUhJ @EU_H2020#dissemination
Some good news 🗞️ to share from our partners @Orbsen and @QUBelfast: Queen's University Belfast’s-led Clinical Trial of Orbsen Therapeutics’ #CellTherapy Completes Recruitment of ICU Patients with #COVID19 https://t.co/VEJv7FeV1q via @PRWeb
Participate in an online survey on teachers’ practices & use of educational technologies during the #COVID19 pandemic by #Scientix, Amgen Teach & @stemalliance_eu! The answers will help shape future actions to support teachers better.
✏️ Link: https://t.co/2z5fxutvVG
NEPHSTROM will deliver and validate a transformative mesenchymal stromal cell (MSC) treatment, ORBCEL-M. MSCs have demonstrated the potential to target the five major aspects of diabetic kidney disease – hypertension, inflammation, fibrosis, oxidative stress, and proteinuria.